ArticleTechnology in cancer research & treatment
Prognostic Factors in Patients With Osteosarcoma With the Surveillance, Epidemiology, and End Results Database.
Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bibliometric analysis of RNA-binding proteins in osteosarcoma: unraveling research trends and hotspots.Frontiers in immunology · 2025Pooled it
- Development and Validation of Nomograms to Assess Risk Factors and Overall Survival Prediction for Lung Metastasis in Young Patients with Osteosarcoma: A SEER-Based Study.International journal of clinical practice · 2022Trial
- Chemokine-Driven Intercellular Crosstalk in the Osteosarcoma Microenvironment After Neoadjuvant Chemotherapy: A Single-Cell RNA Sequencing Study.Biomedicines · 2026Article
- Endobronchial Metastasis From Osteosarcoma in an Adolescent: A Rare Case Report.Thoracic cancer · 2026Article
- Overall Survival and Prognostic Factors in Osteosarcoma: A Nationwide Cohort Study from Taiwan.Life (Basel, Switzerland) · 2026Article
- Development and validation of a novel prognostic signature for osteosarcoma.Translational cancer research · 2025Article
- PDK1, associated with glycolytic metabolism, is a potential prognostic biomarker in osteosarcoma.PloS one · 2025Article
- [Identification of osteoid and chondroid matrix mineralization in primary bone tumors using a deep learning fusion model based on CT and clinical features: a multi-center retrospective study].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Novel lipid metabolism factor HIBCH inhibitor synergizes with doxorubicin to suppress osteosarcoma growth and impacts clinical prognosis in osteosarcoma patients.Journal of bone oncology · 2024Article
- Lipid Peroxidation-Related Redox Signaling in Osteosarcoma.International journal of molecular sciences · 2024Review
- Clinical Features, Risk Factors, and Prediction Nomogram for Primary Spinal Osteosarcoma: A Large-Cohort Retrospective Study.Global spine journal · 2024Article
- Attenuation of Endoplasmic Reticulum Stress Enhances Carvacrol-Induced Apoptosis in Osteosarcoma Cell Lines.Life (Basel, Switzerland) · 2023Article
- Predictors and Treatment Outcomes of Pediatric Osteosarcoma in Diverse Socioeconomic Backgrounds in Southeast Asia: A Retrospective Multicenter Study.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Interpretable clinical visualization model for prediction of prognosis in osteosarcoma: a large cohort data study.Frontiers in oncology · 2022Article
- An External-Validated Prediction Model to Predict Lung Metastasis among Osteosarcoma: A Multicenter Analysis Based on Machine Learning.Computational intelligence and neuroscience · 2022Article
- Risk Factors, Prognostic Factors, and Nomograms for Distant Metastasis in Patients With Newly Diagnosed Osteosarcoma: A Population-Based Study.Frontiers in endocrinology · 2021Article
- Identifying the Best Candidate for Primary Tumor Resection in Patients With Advanced Osteosarcoma.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteosarcoma is a rare type of bone tumor, and this study aimed to assess the clinicopathologic features and prognoses of osteosarcoma patients.
methodsClinicopathologic and survival data of 1025 patients between 2010 and 2016, 230 between 2008 and 2009 were downloaded and analyzed from the SEER database. Patients' survival was analyzed using the Kaplan-Meier analysis; prognostic factors were assessed using the Cox regression hazards model. The 1-, 3-, and 5-year survival rates were estimated with nomogram. Competitive risk models were used to identify prognostic risk factors related to endpoint events of osteosarcoma patients.
resultsOverall, 722 samples were obtained from the extremities, 134 from the axial bones, and 119 from the cranial and mandible in SEER (2010-2016 cohort). After the preliminary diagnosis, the median survival time of patients with osteosarcoma was 39 months, and the 1-, 3-, and 5-year survival rates were 87.3%, 67.2%, and 58.0%, respectively (P < 0.001). The competitive risk model revealed no competitive risks of the endpoint event.
conclusionOur study found out the prognostic factors in patients with Osteosarcoma by Cox regression hazards model, after that, nomogram was established to predict the 1-, 3-, and 5-year survival rates, which may help oncologists to understand the highly malignant tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.